<a id="pl.1.3"></a><var>1.3</var>creating account; providing appointments; requiring rulemaking; requiring <br/>
<a id="pl.1.4"></a><var>1.4</var>reports; appropriating money;amending Minnesota Statutes 2012, section <br/>
<a id="pl.1.5"></a><var>1.5</var>256B.0625, subdivision 13d; proposing coding for new law in Minnesota <br/>
<a id="pl.1.6"></a><var>1.6</var>Statutes, chapter 152.<br/>
<a id="pl.1.7"></a><var>1.7</var>BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:<br/>
<br/>
<a id="bill.0.1.0"></a><a id="pl.1.8"></a><var>1.8</var>    Section 1. <b>[152.22] MEDICAL CANNABIS THERAPEUTIC RESEARCH </b><br/>
<a id="pl.1.9"></a><var>1.9</var><b>STUDY.</b><br/>
<a id="pl.1.10"></a><var>1.10</var>    Subdivision 1. <b>Definitions.</b> (a) For purposes of this section, the following terms <br/>
<a id="pl.1.11"></a><var>1.11</var>have the meanings given.<br/>
<a id="pl.1.12"></a><var>1.12</var>(b) "Commissioner" means the commissioner of health.<br/>
<a id="pl.1.13"></a><var>1.13</var>(c) "Health care practitioner" means a Minnesota licensed doctor of medicine, a <br/>
<a id="pl.1.14"></a><var>1.14</var>Minnesota licensed physician assistant acting within the scope of authorized practice, or a <br/>
<a id="pl.1.15"></a><var>1.15</var>Minnesota licensed advanced practice registered nurse, who has the primary responsibility <br/>
<a id="pl.1.16"></a><var>1.16</var>for the care and treatment of the qualifying medical condition of a person diagnosed with <br/>
<a id="pl.1.17"></a><var>1.17</var>a qualifying medical condition under this section.<br/>
<a id="pl.1.18"></a><var>1.18</var>(d) "Health records" means health record as defined in section 144.291.<br/>
<a id="pl.1.19"></a><var>1.19</var>(e) "Medical cannabis" means the flowers of any species of the genus cannabis plant, <br/>
<a id="pl.1.20"></a><var>1.20</var>or any mixture or preparation of them, including extracts and resins which contain a <br/>
<a id="pl.1.21"></a><var>1.21</var>chemical composition determined to likely be medically beneficial by the commissioner, <br/>
<a id="pl.1.22"></a><var>1.22</var>and that is delivered in the form of:<br/>
<a id="pl.1.23"></a><var>1.23</var>(1) liquid, including, but not limited to, oil;<br/>
<a id="pl.1.24"></a><var>1.24</var>(2) pill;<br/>
<a id="pl.2.1"></a><var>2.1</var>(3) vaporized delivery method with use of liquid or oil but which does not require <br/>
<a id="pl.2.2"></a><var>2.2</var>the use of dried leaves or plant form; or<br/>
<a id="pl.2.3"></a><var>2.3</var>(4) any other method approved by the commissioner but which shall not include <br/>
<a id="pl.2.4"></a><var>2.4</var>smoking.<br/>
<a id="pl.2.5"></a><var>2.5</var>(f) "Medical cannabis manufacturer" or "manufacturer" means an entity registered <br/>
<a id="pl.2.6"></a><var>2.6</var>by the commissioner to cultivate, acquire, manufacture, possess, prepare, transfer, <br/>
<a id="pl.2.7"></a><var>2.7</var>transport, supply, or dispense medical cannabis, delivery devices, or related supplies and <br/>
<a id="pl.2.8"></a><var>2.8</var>educational materials to patients with a qualifying medical condition who are enrolled <br/>
<a id="pl.2.9"></a><var>2.9</var>in the registry program.<br/>
<a id="pl.2.10"></a><var>2.10</var>(g) "Medical cannabis product" means medical cannabis as defined in paragraph <br/>
<a id="pl.2.11"></a><var>2.11</var>(e) and any delivery device or related supplies and educational materials used in the <br/>
<a id="pl.2.12"></a><var>2.12</var>administration of medical cannabis for a patient with a qualifying medical condition <br/>
<a id="pl.2.13"></a><var>2.13</var>enrolled in the registry program.<br/>
<a id="pl.2.14"></a><var>2.14</var>(h) "Patient" means a Minnesota resident who has been diagnosed by a health care <br/>
<a id="pl.2.15"></a><var>2.15</var>practitioner with a qualifying medical condition and who has otherwise met any other <br/>
<a id="pl.2.16"></a><var>2.16</var>requirements of patients under this section to participate in the registry program.<br/>
<a id="pl.2.17"></a><var>2.17</var>(i) "Patient registry number" means a unique identification number assigned to a <br/>
<a id="pl.2.18"></a><var>2.18</var>patient by the commissioner after the commissioner has enrolled the patient in the registry <br/>
<a id="pl.2.19"></a><var>2.19</var>program.<br/>
<a id="pl.2.20"></a><var>2.20</var>(j) "Registered designated caregiver" means a person who is at least 21 years old and <br/>
<a id="pl.2.21"></a><var>2.21</var>who has been approved by the commissioner to assist a patient who has been identified <br/>
<a id="pl.2.22"></a><var>2.22</var>by a health care provider as developmentally or physically disabled and therefore unable <br/>
<a id="pl.2.23"></a><var>2.23</var>to self-administer medication, and who is authorized by the commissioner to administer <br/>
<a id="pl.2.24"></a><var>2.24</var>medical cannabis to the patient only within the patient's primary place of residence;<br/>
<a id="pl.2.25"></a><var>2.25</var>(k) "Registry program" means the patient registry established under this section.<br/>
<a id="pl.2.26"></a><var>2.26</var>(l) "Registry verification" means the verification provided by the commissioner that <br/>
<a id="pl.2.27"></a><var>2.27</var>a patient is enrolled in the registry program and that includes the patient's name, patient <br/>
<a id="pl.2.28"></a><var>2.28</var>registry number, qualifying medical condition, and, if applicable, the name of the patient's <br/>
<a id="pl.2.29"></a><var>2.29</var>registered designated caregiver or parent or legal guardian.<br/>
<a id="pl.2.30"></a><var>2.30</var>(m) "Qualifying medical condition" means a diagnosis of the following conditions:<br/>
<a id="pl.2.31"></a><var>2.31</var>(1) cancer;<br/>
<a id="pl.2.32"></a><var>2.32</var>(2) glaucoma;<br/>
<a id="pl.2.33"></a><var>2.33</var>(3) human immunodeficiency virus or acquired immune deficiency syndrome;<br/>
<a id="pl.2.34"></a><var>2.34</var>(4) Tourette's syndrome;<br/>
<a id="pl.2.35"></a><var>2.35</var>(5) amyotrophic lateral sclerosis;<br/>
<a id="pl.2.36"></a><var>2.36</var>(6) seizures, including those characteristic of epilepsy;<br/>
<a id="pl.3.1"></a><var>3.1</var>(7) severe and persistent muscle spasms, including those characteristic of multiple <br/>
<a id="pl.3.2"></a><var>3.2</var>sclerosis;<br/>
<a id="pl.3.3"></a><var>3.3</var>(8) Crohn's disease; or<br/>
<a id="pl.3.4"></a><var>3.4</var>(9) any other medical condition or its treatment approved by the commissioner.<br/>
<a id="pl.3.5"></a><var>3.5</var>    Subd. 2. <b>Limitations.</b> This section does not permit any person to engage in and <br/>
<a id="pl.3.6"></a><var>3.6</var>does not prevent the imposition of any civil, criminal, or other penalties for:<br/>
<a id="pl.3.7"></a><var>3.7</var>(1) undertaking any task under the influence of medical cannabis that would <br/>
<a id="pl.3.8"></a><var>3.8</var>constitute negligence or professional malpractice;<br/>
<a id="pl.3.9"></a><var>3.9</var>(2) possessing or engaging in the use of medical cannabis on:<br/>
<a id="pl.3.10"></a><var>3.10</var>(i) a school bus or van, which will be punishable in the same manner in which <br/>
<a id="pl.3.11"></a><var>3.11</var>possession of a controlled substance in a school zone is punishable under this chapter;<br/>
<a id="pl.3.12"></a><var>3.12</var>(ii) on the grounds of any preschool or primary or secondary school;<br/>
<a id="pl.3.13"></a><var>3.13</var>(iii) in any correctional facility; or<br/>
<a id="pl.3.14"></a><var>3.14</var>(iv) the grounds of any child care facility or home daycare, which will be punishable <br/>
<a id="pl.3.15"></a><var>3.15</var>in the same manner in which possession of a controlled substance in a school zone <br/>
<a id="pl.3.16"></a><var>3.16</var>is punishable under this chapter;<br/>
<a id="pl.3.17"></a><var>3.17</var>(3) vaporizing medical cannabis pursuant to subdivision 1, paragraph (e):<br/>
<a id="pl.3.18"></a><var>3.18</var>(i) on any form of public transportation;<br/>
<a id="pl.3.19"></a><var>3.19</var>(ii) where the vapor would be inhaled by a nonpatient minor child; or<br/>
<a id="pl.3.20"></a><var>3.20</var>(iii) in any public place; and<br/>
<a id="pl.3.21"></a><var>3.21</var>(4) operating, navigating, or being in actual physical control of any motor vehicle, <br/>
<a id="pl.3.22"></a><var>3.22</var>aircraft, train, or motorboat, or working on transportation property, equipment, or facilities <br/>
<a id="pl.3.23"></a><var>3.23</var>while under the influence of medical cannabis.<br/>
<a id="pl.3.24"></a><var>3.24</var>    Subd. 3. <b>Federally approved clinical trials.</b> The commissioner may prohibit <br/>
<a id="pl.3.25"></a><var>3.25</var>enrollment of a patient in the registry program if the patient is simultaneously enrolled in a <br/>
<a id="pl.3.26"></a><var>3.26</var>federally approved clinical trial for the treatment of a qualifying medical condition with <br/>
<a id="pl.3.27"></a><var>3.27</var>medical cannabis. The commissioner shall provide information to all patients enrolled in <br/>
<a id="pl.3.28"></a><var>3.28</var>the registry program on the existence of federally approved clinical trials for the treatment <br/>
<a id="pl.3.29"></a><var>3.29</var>of the patient's qualifying medical condition with medical cannabis, as an alternative to <br/>
<a id="pl.3.30"></a><var>3.30</var>enrollment in the patient registry program.<br/>
<a id="pl.3.31"></a><var>3.31</var>    Subd. 4. <b>Commissioner duties.</b> (a) The commissioner shall register one in-state <br/>
<a id="pl.3.32"></a><var>3.32</var>manufacturer for the production of all medical cannabis products within the state by <br/>
<a id="pl.3.33"></a><var>3.33</var>December 1, 2014, unless the commissioner obtains an adequate supply of federally <br/>
<a id="pl.3.34"></a><var>3.34</var>sourced medical cannabis products by August 1, 2014. The commissioner shall register <br/>
<a id="pl.3.35"></a><var>3.35</var>a new manufacturer or reregister the existing manufacturer by December 1 of each <br/>
<a id="pl.3.36"></a><var>3.36</var>year, thereafter using the factors described in paragraph (b). The commissioner shall <br/>
<a id="pl.4.1"></a><var>4.1</var>continue to accept applications after December 1, 2014, if no manufacturer that meets <br/>
<a id="pl.4.2"></a><var>4.2</var>the qualifications set forth in this subdivision applies prior to December 1, 2014. The <br/>
<a id="pl.4.3"></a><var>4.3</var>commissioner's determination that no manufacturer exists to fulfill the duties under this <br/>
<a id="pl.4.4"></a><var>4.4</var>section is subject to judicial review in Ramsey County District Court. Data obtained <br/>
<a id="pl.4.5"></a><var>4.5</var>during the application process is governed by section 13.591. As a condition for <br/>
<a id="pl.4.6"></a><var>4.6</var>registration, the commissioner shall require the manufacturer to:<br/>
<a id="pl.4.7"></a><var>4.7</var>(1) supply medical cannabis products to patients by July 1, 2015; and<br/>
<a id="pl.4.8"></a><var>4.8</var>(2) comply with all requirements under subdivision 8.<br/>
<a id="pl.4.9"></a><var>4.9</var>(b) The commissioner shall consider the following factors when determining which <br/>
<a id="pl.4.10"></a><var>4.10</var>manufacturer to register:<br/>
<a id="pl.4.11"></a><var>4.11</var>(1) the technical expertise of the manufacturer in cultivating medical cannabis and <br/>
<a id="pl.4.12"></a><var>4.12</var>converting the medical cannabis into an acceptable delivery method under subdivision 1, <br/>
<a id="pl.4.13"></a><var>4.13</var>paragraph (e);<br/>
<a id="pl.4.14"></a><var>4.14</var>(2) the qualifications of the manufacturer's employees;<br/>
<a id="pl.4.15"></a><var>4.15</var>(3) the long-term financial stability of the manufacturer;<br/>
<a id="pl.4.16"></a><var>4.16</var>(4) the ability to provide appropriate security measures on the premises of the <br/>
<a id="pl.4.17"></a><var>4.17</var>manufacturer;<br/>
<a id="pl.4.18"></a><var>4.18</var>(5) whether the manufacturer has demonstrated an ability to meet the medical <br/>
<a id="pl.4.19"></a><var>4.19</var>cannabis production needs required by this section; and<br/>
<a id="pl.4.20"></a><var>4.20</var>(6) the manufacturer's projection and ongoing assessment of fee levels on patients <br/>
<a id="pl.4.21"></a><var>4.21</var>with a qualifying condition.<br/>
<a id="pl.4.22"></a><var>4.22</var>(c) The commissioner shall require the medical cannabis manufacturer to contract <br/>
<a id="pl.4.23"></a><var>4.23</var>with an independent laboratory to test medical cannabis produced by the manufacturer. <br/>
<a id="pl.4.24"></a><var>4.24</var>The commissioner shall approve the laboratory chosen by the manufacturer and require <br/>
<a id="pl.4.25"></a><var>4.25</var>that the laboratory report testing results to the manufacturer in a manner determined by <br/>
<a id="pl.4.26"></a><var>4.26</var>the commissioner.<br/>
<a id="pl.4.27"></a><var>4.27</var>(d) The commissioner shall review and publicly report the existing medical and <br/>
<a id="pl.4.28"></a><var>4.28</var>scientific literature regarding the range of recommended dosages for each qualifying <br/>
<a id="pl.4.29"></a><var>4.29</var>condition and the range of chemical compositions of any plant of the genus cannabis that <br/>
<a id="pl.4.30"></a><var>4.30</var>will likely be medically beneficial for each of the qualifying medical conditions. The <br/>
<a id="pl.4.31"></a><var>4.31</var>commissioner shall make this information available to patients with qualifying conditions <br/>
<a id="pl.4.32"></a><var>4.32</var>beginning December 1, 2014. The commissioner may consult with the independent <br/>
<a id="pl.4.33"></a><var>4.33</var>laboratory under contract with the manufacturer or other experts in reporting the range of <br/>
<a id="pl.4.34"></a><var>4.34</var>recommended dosage for each qualifying condition, the range of chemical compositions <br/>
<a id="pl.4.35"></a><var>4.35</var>that will likely be medically beneficial, and any risks of noncannabis drug interactions. <br/>
<a id="pl.4.36"></a><var>4.36</var>The commissioner shall consult with the manufacturer on an annual basis on medical <br/>
<a id="pl.5.1"></a><var>5.1</var>cannabis products offered by the manufacturer. The list of medical cannabis products shall <br/>
<a id="pl.5.2"></a><var>5.2</var>be published on the Health Department Web site.<br/>
<a id="pl.5.3"></a><var>5.3</var>(e) The commissioner shall adopt rules necessary for the manufacturer to begin <br/>
<a id="pl.5.4"></a><var>5.4</var>distribution of medical cannabis products to patients under the registry program by July 1, <br/>
<a id="pl.5.5"></a><var>5.5</var>2015, and have notice of proposed rules published in the State Register prior to January <br/>
<a id="pl.5.6"></a><var>5.6</var>1, 2015.<br/>
<a id="pl.5.7"></a><var>5.7</var>(f) The commissioner shall, within 30 days of a deadline listed in this section, advise <br/>
<a id="pl.5.8"></a><var>5.8</var>the public and the co-chairs of the task force on medical cannabis therapeutic research if <br/>
<a id="pl.5.9"></a><var>5.9</var>the commissioner is unable to complete any requirements under this section by the deadline <br/>
<a id="pl.5.10"></a><var>5.10</var>listed in this section. The commissioner shall provide a written statement as to the reason or <br/>
<a id="pl.5.11"></a><var>5.11</var>reasons the deadline will not be met. Upon request of the commissioner, the task force shall <br/>
<a id="pl.5.12"></a><var>5.12</var>extend any deadline by six months, but may not extend any deadline more than three times.<br/>
<a id="pl.5.13"></a><var>5.13</var>(g) The commissioner shall provide regular updates to the task force on medical <br/>
<a id="pl.5.14"></a><var>5.14</var>cannabis therapeutic research regarding any changes in federal law or regulatory <br/>
<a id="pl.5.15"></a><var>5.15</var>restrictions regarding the use of medical cannabis.<br/>
<a id="pl.5.16"></a><var>5.16</var>(h) The commissioner may submit medical research based on the data collected <br/>
<a id="pl.5.17"></a><var>5.17</var>under this section to any federal agency with regulatory or enforcement authority over <br/>
<a id="pl.5.18"></a><var>5.18</var>medical cannabis to demonstrate the efficacy of medical cannabis for treating a qualifying <br/>
<a id="pl.5.19"></a><var>5.19</var>medical condition.<br/>
<a id="pl.5.20"></a><var>5.20</var>    Subd. 5. <b>Rulemaking.</b> The commissioner may adopt rules to implement this <br/>
<a id="pl.5.21"></a><var>5.21</var>section. Rules for which notice is published in the State Register before January 1, 2015 <br/>
<a id="pl.5.22"></a><var>5.22</var>may be adopted using the process in section 14.389.<br/>
<a id="pl.5.23"></a><var>5.23</var>    Subd. 6. <b>Patient registry program established.</b> (a) The commissioner of health <br/>
<a id="pl.5.24"></a><var>5.24</var>shall establish a patient registry program to evaluate data on patient demographics, <br/>
<a id="pl.5.25"></a><var>5.25</var>effective treatment options, clinical outcomes, and quality-of-life outcomes for the purpose <br/>
<a id="pl.5.26"></a><var>5.26</var>of reporting on the benefits, risks, and outcomes regarding patients with a qualifying <br/>
<a id="pl.5.27"></a><var>5.27</var>medical condition engaged in the therapeutic use of medical cannabis.<br/>
<a id="pl.5.28"></a><var>5.28</var>(b) The commissioner shall:<br/>
<a id="pl.5.29"></a><var>5.29</var>(1) give notice of the program to health care practitioners in the state who are <br/>
<a id="pl.5.30"></a><var>5.30</var>eligible to serve as a health care practitioner as defined in subdivision 1, paragraph (c), <br/>
<a id="pl.5.31"></a><var>5.31</var>and explain the purposes and requirements of the program;<br/>
<a id="pl.5.32"></a><var>5.32</var>(2) allow each health care practitioner in the state who meets or agrees to meet the <br/>
<a id="pl.5.33"></a><var>5.33</var>program's requirements and who requests to participate, to be included in the registry <br/>
<a id="pl.5.34"></a><var>5.34</var>program to collect data for the patient registry;<br/>
<a id="pl.6.1"></a><var>6.1</var>(3) provide explanatory information and assistance to each health care practitioner <br/>
<a id="pl.6.2"></a><var>6.2</var>in understanding the nature of therapeutic use of medical cannabis within program <br/>
<a id="pl.6.3"></a><var>6.3</var>requirements;<br/>
<a id="pl.6.4"></a><var>6.4</var>(4) create and provide a certification to be used by a health practitioner for the <br/>
<a id="pl.6.5"></a><var>6.5</var>practitioner to certify whether a patient has been diagnosed with a qualifying medical <br/>
<a id="pl.6.6"></a><var>6.6</var>condition and include in the certification an option for the practitioner to certify whether the <br/>
<a id="pl.6.7"></a><var>6.7</var>patient, in the health care practitioner's medical opinion, is developmentally or physically <br/>
<a id="pl.6.8"></a><var>6.8</var>disabled and, as a result of that disability, the patient is unable to self-administer medication;<br/>
<a id="pl.6.9"></a><var>6.9</var>(5) supervise the participation of the health care practitioner in conducting patient <br/>
<a id="pl.6.10"></a><var>6.10</var>treatment and health records reporting in a manner that ensures stringent security and <br/>
<a id="pl.6.11"></a><var>6.11</var>record-keeping requirements and that prevents the unauthorized release of private data on <br/>
<a id="pl.6.12"></a><var>6.12</var>individuals as defined by section 13.02;<br/>
<a id="pl.6.13"></a><var>6.13</var>(6) develop safety criteria for patients with a qualifying condition as a requirement of <br/>
<a id="pl.6.14"></a><var>6.14</var>the patient's participation in the program, to prevent the patient from undertaking any task <br/>
<a id="pl.6.15"></a><var>6.15</var>under the influence of medical cannabis that would constitute negligence or professional <br/>
<a id="pl.6.16"></a><var>6.16</var>malpractice on the part of the patient; and<br/>
<a id="pl.6.17"></a><var>6.17</var>(7) conduct research and studies based on data from health records submitted to <br/>
<a id="pl.6.18"></a><var>6.18</var>the registry program and submit reports on intermediate or final research results to the <br/>
<a id="pl.6.19"></a><var>6.19</var>legislature and major scientific journals. The commissioner may contract with a third <br/>
<a id="pl.6.20"></a><var>6.20</var>party to complete the requirements of this clause.<br/>
<a id="pl.6.21"></a><var>6.21</var>(c) The commissioner shall develop a patient application for enrollment into the <br/>
<a id="pl.6.22"></a><var>6.22</var>registry program. The application shall be available to the patient and given to health care <br/>
<a id="pl.6.23"></a><var>6.23</var>practitioners in the state who are eligible to serve as a health care practitioner as defined <br/>
<a id="pl.6.24"></a><var>6.24</var>under subdivision 1, paragraph (c). The application must include:<br/>
<a id="pl.6.25"></a><var>6.25</var>(1) the name, mailing address, and date of birth of the qualifying patient;<br/>
<a id="pl.6.26"></a><var>6.26</var>(2) the name, mailing address, and telephone number of the qualifying patient's <br/>
<a id="pl.6.27"></a><var>6.27</var>health care practitioner;<br/>
<a id="pl.6.28"></a><var>6.28</var>(3) the name, mailing address, and date of birth of the patient's designated caregiver, <br/>
<a id="pl.6.29"></a><var>6.29</var>if any, or, if the patient is under age 18, the patient's parent or legal guardian;<br/>
<a id="pl.6.30"></a><var>6.30</var>(4) a copy of the certification from the patient's health care practitioner that is dated <br/>
<a id="pl.6.31"></a><var>6.31</var>within 90 days prior to submitting the application which certifies that the patient has been <br/>
<a id="pl.6.32"></a><var>6.32</var>diagnosed with a qualifying medical condition and, if applicable, that, in the health care <br/>
<a id="pl.6.33"></a><var>6.33</var>practitioner's medical opinion, the patient is developmentally or physically disabled and, <br/>
<a id="pl.6.34"></a><var>6.34</var>as a result of that disability, the patient is unable to self-administer medication; and<br/>
<a id="pl.6.35"></a><var>6.35</var>(5) all other signed affidavits and enrollment forms required by the commissioner <br/>
<a id="pl.6.36"></a><var>6.36</var>under this section, including, but not limited to, the disclosure under paragraph (e).<br/>
<a id="pl.7.1"></a><var>7.1</var>(d) The commissioner shall register a single designated caregiver for a patient if the <br/>
<a id="pl.7.2"></a><var>7.2</var>patient's health care provider certified that the patient, in the health care practitioner's <br/>
<a id="pl.7.3"></a><var>7.3</var>medical opinion, is developmentally or physically disabled and, as a result of that <br/>
<a id="pl.7.4"></a><var>7.4</var>disability, the patient is unable to self-administer medication and the caregiver has agreed, <br/>
<a id="pl.7.5"></a><var>7.5</var>in writing, to be a patient's designated caregiver. As a condition of registration as a <br/>
<a id="pl.7.6"></a><var>7.6</var>designated caregiver, the commissioner shall require the person:<br/>
<a id="pl.7.7"></a><var>7.7</var>(1) to be at least 21 years of age;<br/>
<a id="pl.7.8"></a><var>7.8</var>(2) to not already be registered as a caregiver for another patient enrolled in the <br/>
<a id="pl.7.9"></a><var>7.9</var>registry program;<br/>
<a id="pl.7.10"></a><var>7.10</var>(3) to agree to only possess any medical cannabis product for purposes of <br/>
<a id="pl.7.11"></a><var>7.11</var>administration of the medical cannabis to the patient within the patient's primary place of <br/>
<a id="pl.7.12"></a><var>7.12</var>residence; and<br/>
<a id="pl.7.13"></a><var>7.13</var>(4) to agree that if the application is approved, the patient's designated caregiver will <br/>
<a id="pl.7.14"></a><var>7.14</var>not be a registered designated caregiver for more than one patient.<br/>
<a id="pl.7.15"></a><var>7.15</var>(e) The commissioner shall develop a disclosure form and require, as a condition of <br/>
<a id="pl.7.16"></a><var>7.16</var>enrollment, all patients to sign a copy of the disclosure. The disclosure must include:<br/>
<a id="pl.7.17"></a><var>7.17</var>(1) a statement that notwithstanding any law to the contrary, the commissioner of <br/>
<a id="pl.7.18"></a><var>7.18</var>health, or an employee of any state agency, may not be held civilly or criminally liable for <br/>
<a id="pl.7.19"></a><var>7.19</var>any injury, loss of property, personal injury, or death caused by any act or omission while <br/>
<a id="pl.7.20"></a><var>7.20</var>acting within the scope of office or employment under this section; and<br/>
<a id="pl.7.21"></a><var>7.21</var>(2) the patient's acknowledgement that enrollment in the patient registry program is <br/>
<a id="pl.7.22"></a><var>7.22</var>conditional on the patient's agreement to meet all of the requirements of subdivision 9;<br/>
<a id="pl.7.23"></a><var>7.23</var>(f) After receipt of a patient's application and signed disclosure, the commissioner <br/>
<a id="pl.7.24"></a><var>7.24</var>shall enroll the patient in the registry program and assign the patient a patient registry <br/>
<a id="pl.7.25"></a><var>7.25</var>number. A patient's enrollment in the registry program shall only be denied if the patient:<br/>
<a id="pl.7.26"></a><var>7.26</var>(1) does not have certification from a health care provider that the patient has been <br/>
<a id="pl.7.27"></a><var>7.27</var>diagnosed with a qualifying medical condition; <br/>
<a id="pl.7.28"></a><var>7.28</var>(2) has not signed and returned the disclosure form required under paragraph (d) to <br/>
<a id="pl.7.29"></a><var>7.29</var>the commissioner;<br/>
<a id="pl.7.30"></a><var>7.30</var>(3) does not provide the information required;<br/>
<a id="pl.7.31"></a><var>7.31</var>(4) has previously been removed from the registry program for violations of <br/>
<a id="pl.7.32"></a><var>7.32</var>subdivision 9; or<br/>
<a id="pl.7.33"></a><var>7.33</var>(5) provides false information.<br/>
<a id="pl.7.34"></a><var>7.34</var>(g) The commissioner shall give written notice to a patient of the reason for denying <br/>
<a id="pl.7.35"></a><var>7.35</var>enrollment in the registry program.<br/>
<a id="pl.8.1"></a><var>8.1</var>(h) Denial of enrollment into the registry program is considered a final decision of <br/>
<a id="pl.8.2"></a><var>8.2</var>the commissioner and is subject to judicial review under the Administrative Procedure <br/>
<a id="pl.8.3"></a><var>8.3</var>Act pursuant to chapter 14.<br/>
<a id="pl.8.4"></a><var>8.4</var>(i) A patient's enrollment in the registry program may only be revoked if a patient <br/>
<a id="pl.8.5"></a><var>8.5</var>violates a requirement in subdivision 9.<br/>
<a id="pl.8.6"></a><var>8.6</var>(j) The commissioner shall develop a registry verification to provide to the health <br/>
<a id="pl.8.7"></a><var>8.7</var>care practitioner identified in the patient's application and to the manufacturer. The <br/>
<a id="pl.8.8"></a><var>8.8</var>registry verification shall include:<br/>
<a id="pl.8.9"></a><var>8.9</var>(1) the patient's name and date of birth;<br/>
<a id="pl.8.10"></a><var>8.10</var>(2) the patient registry number assigned to the patient;<br/>
<a id="pl.8.11"></a><var>8.11</var>(3) the patient's qualifying medical condition as provided by the patient's health care <br/>
<a id="pl.8.12"></a><var>8.12</var>provider in the certification; and<br/>
<a id="pl.8.13"></a><var>8.13</var>(4) the name and date of birth of the patient's registered designated caregiver, if any, <br/>
<a id="pl.8.14"></a><var>8.14</var>or, if the patient is under age 18, the name of the patient's parent or legal guardian.<br/>
<a id="pl.8.15"></a><var>8.15</var>(k) If the commissioner adds a delivery form under subdivision 1, paragraph (e), or a <br/>
<a id="pl.8.16"></a><var>8.16</var>qualifying medical condition under subdivision 1, paragraph (m), the commissioner shall <br/>
<a id="pl.8.17"></a><var>8.17</var>notify the legislature by January 15 of any year in which the commissioner wishes to make <br/>
<a id="pl.8.18"></a><var>8.18</var>the change. The change shall be effective on August 1 of that year, unless the legislature <br/>
<a id="pl.8.19"></a><var>8.19</var>by law provides otherwise. As part of the January submission, the commissioner shall <br/>
<a id="pl.8.20"></a><var>8.20</var>notify the chairs and ranking minority members of the legislative policy committees <br/>
<a id="pl.8.21"></a><var>8.21</var>having jurisdiction over health and public safety of the addition and the reasons for its <br/>
<a id="pl.8.22"></a><var>8.22</var>addition, including any written comments received by the commissioner from the public <br/>
<a id="pl.8.23"></a><var>8.23</var>and any guidance received from the task force on medical cannabis research.<br/>
<a id="pl.8.24"></a><var>8.24</var>(l) Nothing in this section requires the medical assistance and MinnesotaCare <br/>
<a id="pl.8.25"></a><var>8.25</var>programs to reimburse an enrollee or a provider for costs associated with the medical use <br/>
<a id="pl.8.26"></a><var>8.26</var>of cannabis. Medical assistance and MinnesotaCare shall continue to reimburse providers <br/>
<a id="pl.8.27"></a><var>8.27</var>for covered services related to treatment of a recipient's qualifying medical condition.<br/>
<a id="pl.8.28"></a><var>8.28</var>(m) The establishment of the registry program is not intended in any manner <br/>
<a id="pl.8.29"></a><var>8.29</var>whatsoever to condone or promote the illicit recreational use of marijuana.<br/>
<a id="pl.8.30"></a><var>8.30</var>    Subd. 7. <b>Health care practitioner duties.</b> (a) Prior to a patient's enrollment in the <br/>
<a id="pl.8.31"></a><var>8.31</var>registry program, a health care practitioner shall:<br/>
<a id="pl.8.32"></a><var>8.32</var>(1) determine, in the health care practitioner's medical judgment, whether a patient <br/>
<a id="pl.8.33"></a><var>8.33</var>suffers from a qualifying medical condition as defined in subdivision 1, paragraph (m), <br/>
<a id="pl.8.34"></a><var>8.34</var>and if so determined, provide the patient with a certification of that diagnosis;<br/>
<a id="pl.9.1"></a><var>9.1</var>(2) determine whether a patient is developmentally or physically disabled and, as <br/>
<a id="pl.9.2"></a><var>9.2</var>a result of that disability, the patient is unable to self-administer medication, and, if so <br/>
<a id="pl.9.3"></a><var>9.3</var>determined, include that determination on the patient's certification of diagnosis; <br/>
<a id="pl.9.4"></a><var>9.4</var>(3) advise patients, registered designated caregivers, and parents or legal guardians <br/>
<a id="pl.9.5"></a><var>9.5</var>of patients under age 18 of the existence of any nonprofit patient support groups or <br/>
<a id="pl.9.6"></a><var>9.6</var>organizations;<br/>
<a id="pl.9.7"></a><var>9.7</var>(4) provide explanatory information from the commissioner to patients with <br/>
<a id="pl.9.8"></a><var>9.8</var>qualifying medical conditions, including disclosure to all patients about the experimental <br/>
<a id="pl.9.9"></a><var>9.9</var>nature of therapeutic use of medical cannabis, the possible risks and side effects of the <br/>
<a id="pl.9.10"></a><var>9.10</var>proposed treatment, the application and other materials from the commissioner, and provide <br/>
<a id="pl.9.11"></a><var>9.11</var>patients with the Tennessen warning as required by section 13.04, subdivision 2; and<br/>
<a id="pl.9.12"></a><var>9.12</var>(5) agree to continue treatment of the patient's qualifying medical condition and <br/>
<a id="pl.9.13"></a><var>9.13</var>report medical findings to the commissioner.<br/>
<a id="pl.9.14"></a><var>9.14</var>(b) Upon notification from the commissioner of the patient's enrollment in the <br/>
<a id="pl.9.15"></a><var>9.15</var>registry program, the health care practitioner shall:<br/>
<a id="pl.9.16"></a><var>9.16</var>(1) participate in the patient registry reporting system under the guidance and <br/>
<a id="pl.9.17"></a><var>9.17</var>supervision of the commissioner of health;<br/>
<a id="pl.9.18"></a><var>9.18</var>(2) report health records of the patient throughout the ongoing treatment of the <br/>
<a id="pl.9.19"></a><var>9.19</var>patient to the commissioner in a manner determined by the commissioner of health and in <br/>
<a id="pl.9.20"></a><var>9.20</var>accordance with paragraph (c); and<br/>
<a id="pl.9.21"></a><var>9.21</var>(3) otherwise comply with all requirements developed by the commissioner.<br/>
<a id="pl.9.22"></a><var>9.22</var>(c) Data collected on patients by a health care practitioner and reported to the patient <br/>
<a id="pl.9.23"></a><var>9.23</var>registry are health records under section 144.291 and are private data on individuals under <br/>
<a id="pl.9.24"></a><var>9.24</var>section 13.02 but may be used or reported in an aggregated, nonidentifiable form as part of <br/>
<a id="pl.9.25"></a><var>9.25</var>a scientific, peer-reviewed publication of research conducted under this section or in the <br/>
<a id="pl.9.26"></a><var>9.26</var>creation of summary data, as defined in section 13.02, subdivision 19.<br/>
<a id="pl.9.27"></a><var>9.27</var>(d) Nothing in this section requires a health care practitioner to enroll patients in the <br/>
<a id="pl.9.28"></a><var>9.28</var>registry created by this section.<br/>
<a id="pl.9.29"></a><var>9.29</var>    Subd. 8. <b>Manufacturer of medical cannabis duties.</b> (a) The manufacturer of <br/>
<a id="pl.9.30"></a><var>9.30</var>medical cannabis shall provide a reliable and ongoing supply of all medical cannabis <br/>
<a id="pl.9.31"></a><var>9.31</var>products needed for the registry program.<br/>
<a id="pl.9.32"></a><var>9.32</var>(b) All cultivation, harvesting, manufacturing, and packing of cannabis must take <br/>
<a id="pl.9.33"></a><var>9.33</var>place in an enclosed, locked facility at a physical address provided to the commissioner <br/>
<a id="pl.9.34"></a><var>9.34</var>during the registration process.<br/>
<a id="pl.9.35"></a><var>9.35</var>(c) The manufacturer may operate up to two satellite distribution centers, located <br/>
<a id="pl.9.36"></a><var>9.36</var>throughout the state to improve patient access, where the manufacturer may distribute <br/>
<a id="pl.10.1"></a><var>10.1</var>medical cannabis products in addition to the manufacturer's primary location. The <br/>
<a id="pl.10.2"></a><var>10.2</var>manufacturer shall disclose the proposed locations for the distribution centers to the <br/>
<a id="pl.10.3"></a><var>10.3</var>commissioner during the registration process. The distribution centers may not contain <br/>
<a id="pl.10.4"></a><var>10.4</var>any medical cannabis products in a form other than those forms allowed under subdivision <br/>
<a id="pl.10.5"></a><var>10.5</var>1, paragraph (e), and the manufacturer shall not conduct any cultivation, harvesting, <br/>
<a id="pl.10.6"></a><var>10.6</var>manufacturing, packaging, or processing at the distribution center site. Any distribution <br/>
<a id="pl.10.7"></a><var>10.7</var>center operated by the manufacturer is subject to all of the requirements applying to the <br/>
<a id="pl.10.8"></a><var>10.8</var>manufacturer under this subdivision, including, but not limited to, security and distribution <br/>
<a id="pl.10.9"></a><var>10.9</var>requirements.<br/>
<a id="pl.10.10"></a><var>10.10</var>(d) The medical cannabis manufacturer shall produce medical cannabis with <br/>
<a id="pl.10.11"></a><var>10.11</var>chemical compositions as determined by the commissioner.<br/>
<a id="pl.10.12"></a><var>10.12</var>(e) The medical cannabis manufacturer shall contract with a laboratory, subject to <br/>
<a id="pl.10.13"></a><var>10.13</var>the commissioner's approval of the laboratory and any additional requirements set by the <br/>
<a id="pl.10.14"></a><var>10.14</var>commissioner, for purposes of testing medical cannabis manufactured by the medical <br/>
<a id="pl.10.15"></a><var>10.15</var>cannabis manufacturer as to content, contamination, and consistency to verify the medical <br/>
<a id="pl.10.16"></a><var>10.16</var>cannabis meets the requirements of subdivision 1, paragraph (e). The cost of lab testing <br/>
<a id="pl.10.17"></a><var>10.17</var>shall be paid by the manufacturer.<br/>
<a id="pl.10.18"></a><var>10.18</var>(f) The manufacturer must process and prepare any cannabis plant material into a form <br/>
<a id="pl.10.19"></a><var>10.19</var>allowable under subdivision 1, paragraph (e), prior to distribution of any medical cannabis.<br/>
<a id="pl.10.20"></a><var>10.20</var>(g) The manufacturer shall require that any employee licensed as a pharmacist <br/>
<a id="pl.10.21"></a><var>10.21</var>pursuant to chapter 151 and the rules promulgated pursuant to that chapter be the only <br/>
<a id="pl.10.22"></a><var>10.22</var>employees to distribute the medical cannabis to a patient.<br/>
<a id="pl.10.23"></a><var>10.23</var>(h) The manufacturer shall only distribute medical cannabis products to the patient <br/>
<a id="pl.10.24"></a><var>10.24</var>or, if the patient is under age 18, to the patient's parent or legal guardian.<br/>
<a id="pl.10.25"></a><var>10.25</var>(i) Prior to distribution of any medical cannabis products to any patient or, if the <br/>
<a id="pl.10.26"></a><var>10.26</var>patient is under age 18, the patient's parent of legal guardian, the manufacturer shall:<br/>
<a id="pl.10.27"></a><var>10.27</var>(1) verify that the manufacturer has received the registry verification from the <br/>
<a id="pl.10.28"></a><var>10.28</var>commissioner for that individual patient;<br/>
<a id="pl.10.29"></a><var>10.29</var>(2) verify that the person requesting the distribution of medical cannabis is the <br/>
<a id="pl.10.30"></a><var>10.30</var>patient, or, if the patient is under age 18, the patient's parent or legal guardian, listed in the <br/>
<a id="pl.10.31"></a><var>10.31</var>registry verification, in accordance with section 152.11, subdivision 2d;<br/>
<a id="pl.10.32"></a><var>10.32</var>(3) assign a tracking number to each individual medical cannabis product;<br/>
<a id="pl.10.33"></a><var>10.33</var>(4) ensure that any employee of the manufacturer licensed as a pharmacist pursuant <br/>
<a id="pl.10.34"></a><var>10.34</var>to chapter 151 and the rules promulgated pursuant to that chapter has consulted with the <br/>
<a id="pl.10.35"></a><var>10.35</var>patient to determine the proper dosage for the individual patient based on the ranges of <br/>
<a id="pl.11.1"></a><var>11.1</var>chemical compositions of the medical cannabis and the ranges of proper dosages reported <br/>
<a id="pl.11.2"></a><var>11.2</var>by the commissioner;<br/>
<a id="pl.11.3"></a><var>11.3</var>(5) properly label each medical cannabis product with individually identifying <br/>
<a id="pl.11.4"></a><var>11.4</var>information, including:<br/>
<a id="pl.11.5"></a><var>11.5</var>(i) the patient's name and date of birth;<br/>
<a id="pl.11.6"></a><var>11.6</var>(ii) the name and date of birth of the patient's registered designated caregiver, or, <br/>
<a id="pl.11.7"></a><var>11.7</var>if the patient is under age 18, the name of the patient's parent or legal guardian, if either <br/>
<a id="pl.11.8"></a><var>11.8</var>were included on the registry verification;<br/>
<a id="pl.11.9"></a><var>11.9</var>(iii) the patient's registry number;<br/>
<a id="pl.11.10"></a><var>11.10</var>(iv) the chemical composition of the medical cannabis; and<br/>
<a id="pl.11.11"></a><var>11.11</var>(v) the dosage; and<br/>
<a id="pl.11.12"></a><var>11.12</var>(6) ensure that the medical cannabis distributed to a patient contains a maximum of a <br/>
<a id="pl.11.13"></a><var>11.13</var>30-day supply of the dosage determined for that patient.<br/>
<a id="pl.11.14"></a><var>11.14</var>(j) If the patient has a registered designated caregiver, the manufacturer shall deliver <br/>
<a id="pl.11.15"></a><var>11.15</var>properly labeled medical cannabis products to the patient or the patient's registered <br/>
<a id="pl.11.16"></a><var>11.16</var>designated caregiver but only at the patient's primary residence. The manufacturer shall <br/>
<a id="pl.11.17"></a><var>11.17</var>verify that the person to whom the medical cannabis product is being delivered is either <br/>
<a id="pl.11.18"></a><var>11.18</var>the patient or the patient's registered designated caregiver, in accordance with section <br/>
<a id="pl.11.19"></a><var>11.19</var>152.11, subdivision 2d. The manufacturer shall not distribute medical cannabis products <br/>
<a id="pl.11.20"></a><var>11.20</var>to a registered designated caregiver at the premises of the manufacturer.<br/>
<a id="pl.11.21"></a><var>11.21</var>(k) The manufacturer shall report to the commissioner, on a monthly basis, the <br/>
<a id="pl.11.22"></a><var>11.22</var>following information on each individual patient from the month prior to the report:<br/>
<a id="pl.11.23"></a><var>11.23</var>(1) the amount and dosages of medical cannabis products distributed;<br/>
<a id="pl.11.24"></a><var>11.24</var>(2) the chemical composition of the medical cannabis; and<br/>
<a id="pl.11.25"></a><var>11.25</var>(3) the tracking number assigned to any medical cannabis product distributed.<br/>
<a id="pl.11.26"></a><var>11.26</var>(l) The operating documents of the manufacturer must include:<br/>
<a id="pl.11.27"></a><var>11.27</var>(1) procedures for the oversight of the manufacturer and procedures to ensure <br/>
<a id="pl.11.28"></a><var>11.28</var>accurate record keeping; and <br/>
<a id="pl.11.29"></a><var>11.29</var>(2) procedures for the implementation of appropriate security measures to deter and <br/>
<a id="pl.11.30"></a><var>11.30</var>prevent the theft of cannabis and unauthorized entrance into areas containing cannabis.<br/>
<a id="pl.11.31"></a><var>11.31</var>(m) The manufacturer shall not share office space with, refer patients to a health care <br/>
<a id="pl.11.32"></a><var>11.32</var>practitioner, or have any financial relationship with a health care practitioner.<br/>
<a id="pl.11.33"></a><var>11.33</var>(n) The manufacturer shall not permit any person to consume cannabis on the <br/>
<a id="pl.11.34"></a><var>11.34</var>property of the manufacturer.<br/>
<a id="pl.11.35"></a><var>11.35</var>(o) The manufacturer is subject to reasonable inspection by the commissioner.<br/>
<a id="pl.12.1"></a><var>12.1</var>(p) For purposes of this section only, the medical cannabis manufacturer is not <br/>
<a id="pl.12.2"></a><var>12.2</var>subject to the Board of Pharmacy licensure or regulatory requirements under chapter 151.<br/>
<a id="pl.12.3"></a><var>12.3</var>(q) A medical cannabis manufacturer may not employ or otherwise allow any person <br/>
<a id="pl.12.4"></a><var>12.4</var>who is under 21 years of age or who has been convicted of a disqualifying felony offense <br/>
<a id="pl.12.5"></a><var>12.5</var>to be an employee of the medical cannabis organization. For purposes of this paragraph, a <br/>
<a id="pl.12.6"></a><var>12.6</var>disqualifying felony offense means a violation of a state or federal controlled substance law <br/>
<a id="pl.12.7"></a><var>12.7</var>that is classified as a felony under Minnesota law, or would be classified as a felony under <br/>
<a id="pl.12.8"></a><var>12.8</var>Minnesota law if committed in Minnesota, regardless of the sentence imposed, unless the <br/>
<a id="pl.12.9"></a><var>12.9</var>person's conviction was for the medical use of cannabis or assisting with the medical use <br/>
<a id="pl.12.10"></a><var>12.10</var>of cannabis in accordance with any other state's law. An employee of a medical cannabis <br/>
<a id="pl.12.11"></a><var>12.11</var>manufacturer must submit a completed criminal history records check consent form, a <br/>
<a id="pl.12.12"></a><var>12.12</var>full set of fingerprints and the required fees for submission to the Bureau of Criminal <br/>
<a id="pl.12.13"></a><var>12.13</var>Apprehension before an employee may begin working with the manufacturer. The bureau <br/>
<a id="pl.12.14"></a><var>12.14</var>must conduct a Minnesota criminal history records check and the superintendent is <br/>
<a id="pl.12.15"></a><var>12.15</var>authorized to exchange the fingerprints with the Federal Bureau of Investigation to obtain <br/>
<a id="pl.12.16"></a><var>12.16</var>the applicant's national criminal history record information. The bureau will return the <br/>
<a id="pl.12.17"></a><var>12.17</var>results of the Minnesota and federal criminal history records checks to the commissioner.<br/>
<a id="pl.12.18"></a><var>12.18</var>    Subd. 9. <b>Patient duties.</b> (a) A patient shall apply to the commissioner for enrollment <br/>
<a id="pl.12.19"></a><var>12.19</var>in the registry program by submitting an application, as defined in subdivision 6, paragraph <br/>
<a id="pl.12.20"></a><var>12.20</var>(c), and an annual registration fee as determined under subdivision 13, paragraph (a).<br/>
<a id="pl.12.21"></a><var>12.21</var>(b) As a condition of continued enrollment, a patient shall agree to:<br/>
<a id="pl.12.22"></a><var>12.22</var>(1) continue to receive regularly scheduled treatment for their qualifying medical <br/>
<a id="pl.12.23"></a><var>12.23</var>condition from their health care practitioner; and<br/>
<a id="pl.12.24"></a><var>12.24</var>(2) report changes in their qualifying medical condition to their health care <br/>
<a id="pl.12.25"></a><var>12.25</var>practitioner.<br/>
<a id="pl.12.26"></a><var>12.26</var>    Subd. 10. <b>Data practices.</b> (a) Government data in patient files maintained by the <br/>
<a id="pl.12.27"></a><var>12.27</var>commissioner and the health care practitioner, and data submitted to or by the medical <br/>
<a id="pl.12.28"></a><var>12.28</var>cannabis manufacturer, are private data on individuals, as defined in section 13.02, <br/>
<a id="pl.12.29"></a><var>12.29</var>subdivision 12, or nonpublic data, as defined in section 13.02, subdivision 9, and may be <br/>
<a id="pl.12.30"></a><var>12.30</var>used for purposes of complying with chapter 13 and complying with a request from the <br/>
<a id="pl.12.31"></a><var>12.31</var>legislative auditor in the performance of official duties. The provisions of section 13.05, <br/>
<a id="pl.12.32"></a><var>12.32</var>subdivision 11, apply to a registration agreement entered between the commissioner and a <br/>
<a id="pl.12.33"></a><var>12.33</var>medical cannabis manufacturer under this section.<br/>
<a id="pl.12.34"></a><var>12.34</var>(b) Not public data maintained by the commissioner may not be used for any <br/>
<a id="pl.12.35"></a><var>12.35</var>purpose not provided for in this section, and may not be combined or linked in any manner <br/>
<a id="pl.12.36"></a><var>12.36</var>with any other list, dataset, or database.<br/>
<a id="pl.13.1"></a><var>13.1</var>    Subd. 11. <b>Protections for registry program participation; criminal and civil.</b> (a) <br/>
<a id="pl.13.2"></a><var>13.2</var>There is a presumption that a patient enrolled in the registry program under this section is <br/>
<a id="pl.13.3"></a><var>13.3</var>engaged in the authorized use of medical cannabis.<br/>
<a id="pl.13.4"></a><var>13.4</var>(b) The presumption may be rebutted by evidence that conduct related to use of <br/>
<a id="pl.13.5"></a><var>13.5</var>medical cannabis was not for the purpose of treating or alleviating the patient's qualifying <br/>
<a id="pl.13.6"></a><var>13.6</var>medical condition or symptoms associated with the patient's qualifying medical condition <br/>
<a id="pl.13.7"></a><var>13.7</var>pursuant to this section.<br/>
<a id="pl.13.8"></a><var>13.8</var>(c) For the purposes of this section only, subject to subdivision 2, the following are <br/>
<a id="pl.13.9"></a><var>13.9</var>not violations under this chapter:<br/>
<a id="pl.13.10"></a><var>13.10</var>(1) use or possession of medical cannabis products by a patient enrolled in the <br/>
<a id="pl.13.11"></a><var>13.11</var>registry program, or possession by the parent or guardian of a patient under age 18;<br/>
<a id="pl.13.12"></a><var>13.12</var>(2) possession of medical cannabis products by a registered designated caregiver, <br/>
<a id="pl.13.13"></a><var>13.13</var>only if the registered designated caregiver is in possession of the medical cannabis <br/>
<a id="pl.13.14"></a><var>13.14</var>products within the primary residence of the individual patient in which the caregiver has <br/>
<a id="pl.13.15"></a><var>13.15</var>been registered to assist;<br/>
<a id="pl.13.16"></a><var>13.16</var>(3) possession, dosage determination, or sale of medical cannabis products by the <br/>
<a id="pl.13.17"></a><var>13.17</var>medical cannabis manufacturer, employees of the manufacturer, the laboratory conducting <br/>
<a id="pl.13.18"></a><var>13.18</var>testing on medical marijuana products, or employees of the laboratory; and<br/>
<a id="pl.13.19"></a><var>13.19</var>(4) possession of medical cannabis products by any person while carrying out the <br/>
<a id="pl.13.20"></a><var>13.20</var>duties required under this section.<br/>
<a id="pl.13.21"></a><var>13.21</var>(d) Medical cannabis obtained and distributed pursuant to this section and associated <br/>
<a id="pl.13.22"></a><var>13.22</var>property is not subject to forfeiture under sections 609.531 to 609.5316.<br/>
<a id="pl.13.23"></a><var>13.23</var>(e) The commissioner, the commissioner's staff, the commissioner's agents or <br/>
<a id="pl.13.24"></a><var>13.24</var>contractors and any health care practitioner are not subject to any civil or disciplinary <br/>
<a id="pl.13.25"></a><var>13.25</var>penalties by the Board of Medical Practice or by any business, occupational, or <br/>
<a id="pl.13.26"></a><var>13.26</var>professional licensing board or entity, solely for the participation in the registry program <br/>
<a id="pl.13.27"></a><var>13.27</var>under this section. Nothing in this section prohibits a professional licensing board for <br/>
<a id="pl.13.28"></a><var>13.28</var>sanctioning actions outside of those actions allowed under this section.<br/>
<a id="pl.13.29"></a><var>13.29</var>(f) Notwithstanding any law to the contrary, the commissioner of health, the <br/>
<a id="pl.13.30"></a><var>13.30</var>governor of Minnesota, or an employee of any state agency, may not be held civilly or <br/>
<a id="pl.13.31"></a><var>13.31</var>criminally liable for any injury, loss of property, personal injury, or death caused by any <br/>
<a id="pl.13.32"></a><var>13.32</var>act or omission while acting within the scope of office or employment under this section.<br/>
<a id="pl.13.33"></a><var>13.33</var>(g) Federal, state, and local law enforcement authorities are prohibited from accessing <br/>
<a id="pl.13.34"></a><var>13.34</var>the patient registry under this section except when acting pursuant to a valid search warrant. <br/>
<a id="pl.13.35"></a><var>13.35</var>(h) Notwithstanding any law to the contrary, neither the commissioner nor a public <br/>
<a id="pl.13.36"></a><var>13.36</var>employee may release data or information about an individual contained in any report, <br/>
<a id="pl.14.1"></a><var>14.1</var>document, or registry created under this section or any information obtained about a <br/>
<a id="pl.14.2"></a><var>14.2</var>patient participating in the program, except as provided in this section. No information <br/>
<a id="pl.14.3"></a><var>14.3</var>contained in a report, document, registry, or obtained from a patient under this section <br/>
<a id="pl.14.4"></a><var>14.4</var>may be used against a patient in a criminal proceeding unless independently obtained or in <br/>
<a id="pl.14.5"></a><var>14.5</var>connection with a proceeding involving a violation of this section.<br/>
<a id="pl.14.6"></a><var>14.6</var>(i) Any person who violates paragraph (g) or (h) is guilty of a gross misdemeanor.<br/>
<a id="pl.14.7"></a><var>14.7</var>    Subd. 12. <b>Discrimination prohibited.</b> (a) No school or landlord may refuse to <br/>
<a id="pl.14.8"></a><var>14.8</var>enroll or lease to and may not otherwise penalize a person solely for the person's status as <br/>
<a id="pl.14.9"></a><var>14.9</var>a patient enrolled in the registry program under this section, unless failing to do so would <br/>
<a id="pl.14.10"></a><var>14.10</var>violate federal law or regulations or cause the school or landlord to lose a monetary or <br/>
<a id="pl.14.11"></a><var>14.11</var>licensing-related benefit under federal law or regulations.<br/>
<a id="pl.14.12"></a><var>14.12</var>(b) For the purposes of medical care, including organ transplants, a registry program <br/>
<a id="pl.14.13"></a><var>14.13</var>enrollee's use of medical cannabis under this section is considered the equivalent of the <br/>
<a id="pl.14.14"></a><var>14.14</var>authorized use of any other medication used at the discretion of a physician and does <br/>
<a id="pl.14.15"></a><var>14.15</var>not constitute the use of an illicit substance or otherwise disqualify a qualifying patient <br/>
<a id="pl.14.16"></a><var>14.16</var>from needed medical care.<br/>
<a id="pl.14.17"></a><var>14.17</var>(c) Unless a failure to do so would violate federal law or regulations or cause an <br/>
<a id="pl.14.18"></a><var>14.18</var>employer to lose a monetary or licensing-related benefit under federal law or regulations, <br/>
<a id="pl.14.19"></a><var>14.19</var>an employer may not discriminate against a person in hiring, termination, or any term or <br/>
<a id="pl.14.20"></a><var>14.20</var>condition of employment, or otherwise penalize a person, if the discrimination is based <br/>
<a id="pl.14.21"></a><var>14.21</var>upon either of the following:<br/>
<a id="pl.14.22"></a><var>14.22</var>(1) the person's status as a patient enrolled in the registry program under this section; <br/>
<a id="pl.14.23"></a><var>14.23</var>or<br/>
<a id="pl.14.24"></a><var>14.24</var>(2) a patient's positive drug test for cannabis components or metabolites, unless the <br/>
<a id="pl.14.25"></a><var>14.25</var>patient used, possessed, or was impaired by medical cannabis on the premises of the place <br/>
<a id="pl.14.26"></a><var>14.26</var>of employment or during the hours of employment.<br/>
<a id="pl.14.27"></a><var>14.27</var>(d) A person shall not be denied custody of or visitation rights or parenting time <br/>
<a id="pl.14.28"></a><var>14.28</var>with a minor solely for the person's status as a patient enrolled in the registry program <br/>
<a id="pl.14.29"></a><var>14.29</var>under this section, and there shall be no presumption of neglect or child endangerment <br/>
<a id="pl.14.30"></a><var>14.30</var>for conduct allowed under this section, unless the person's behavior is such that it creates <br/>
<a id="pl.14.31"></a><var>14.31</var>an unreasonable danger to the safety of the minor as established by clear and convincing <br/>
<a id="pl.14.32"></a><var>14.32</var>evidence.<br/>
<a id="pl.14.33"></a><var>14.33</var>    Subd. 13. <b>Fees; deposit of revenue.</b> (a) The commissioner shall collect an <br/>
<a id="pl.14.34"></a><var>14.34</var>enrollment fee of $200 from qualified patients enrolled under this section. If the patient <br/>
<a id="pl.14.35"></a><var>14.35</var>attests to receiving Social Security disability, Supplemental Security Insurance payments, <br/>
<a id="pl.14.36"></a><var>14.36</var>or being enrolled in medical assistance or MinnesotaCare then the fee shall be $50. <br/>
<a id="pl.15.1"></a><var>15.1</var>The fees shall be payable annually and are due on the anniversary date of the patient's <br/>
<a id="pl.15.2"></a><var>15.2</var>enrollment. The fee amount shall be deposited in the state treasury and credited to the <br/>
<a id="pl.15.3"></a><var>15.3</var>state government special revenue fund.<br/>
<a id="pl.15.4"></a><var>15.4</var>(b) The commissioner shall collect an application fee of $20,000 from each entity <br/>
<a id="pl.15.5"></a><var>15.5</var>submitting an application for registration as a medical cannabis manufacturer. Revenue <br/>
<a id="pl.15.6"></a><var>15.6</var>from the fee shall be deposited in the state treasury and credited to the state government <br/>
<a id="pl.15.7"></a><var>15.7</var>special revenue fund. If an entity is not selected to be registered as a medical cannabis <br/>
<a id="pl.15.8"></a><var>15.8</var>manufacturer, the commissioner shall refund $19,000 to the entity.<br/>
<a id="pl.15.9"></a><var>15.9</var>(c) The commissioner shall collect an annual fee from a medical cannabis <br/>
<a id="pl.15.10"></a><var>15.10</var>manufacturer equal to the cost of regulating and inspecting the manufacturer in that year. <br/>
<a id="pl.15.11"></a><var>15.11</var>Revenue from the fee amount shall be deposited in the state treasury and credited to <br/>
<a id="pl.15.12"></a><var>15.12</var>the state government special revenue fund.<br/>
<a id="pl.15.13"></a><var>15.13</var>(d) The medical cannabis manufacturer may charge patients enrolled in the registry <br/>
<a id="pl.15.14"></a><var>15.14</var>program a reasonable fee for costs associated with the operations of the manufacturer. <br/>
<a id="pl.15.15"></a><var>15.15</var>The manufacturer may charge fees associated with the delivery of medical cannabis <br/>
<a id="pl.15.16"></a><var>15.16</var>pursuant to subdivision 8, paragraph (i), but shall only charge the fee to those patients <br/>
<a id="pl.15.17"></a><var>15.17</var>who received the delivery service. The manufacturer may establish a sliding scale of <br/>
<a id="pl.15.18"></a><var>15.18</var>patient fees based upon a qualifying patient's household income and may accept private <br/>
<a id="pl.15.19"></a><var>15.19</var>donations to reduce patient fees.<br/>
<a id="pl.15.20"></a><var>15.20</var>    Subd. 14. <b>Nursing facilities.</b> Nursing facilities licensed under chapter 144A, or <br/>
<a id="pl.15.21"></a><var>15.21</var>boarding care homes licensed under section 144.50, may adopt reasonable restrictions on <br/>
<a id="pl.15.22"></a><var>15.22</var>the use of medical cannabis by persons receiving services. The restrictions may include a <br/>
<a id="pl.15.23"></a><var>15.23</var>provision that the facility will not store or maintain the patient's supply of medical cannabis, <br/>
<a id="pl.15.24"></a><var>15.24</var>that the facility is not responsible for providing the medical cannabis for qualifying patients, <br/>
<a id="pl.15.25"></a><var>15.25</var>and that medical cannabis be consumed only in a place specified by the facility. Nothing <br/>
<a id="pl.15.26"></a><var>15.26</var>contained in this section shall require the facilities to adopt such restrictions, and no <br/>
<a id="pl.15.27"></a><var>15.27</var>facility shall unreasonably limit a qualifying patient's access to or use of medical cannabis.<br/>
<br/>
<a id="bill.0.2.0"></a><a id="pl.15.28"></a><var>15.28</var>    Sec. 2. <b>[152.24] IMPACT ASSESSMENT OF MEDICAL CANNABIS </b><br/>
<a id="pl.15.29"></a><var>15.29</var><b>THERAPEUTIC RESEARCH.</b><br/>
<a id="pl.15.30"></a><var>15.30</var>    Subdivision 1. <b>Task force on medical cannabis therapeutic research.</b> (a) A <br/>
<a id="pl.15.31"></a><var>15.31</var>23-member task force on medical cannabis therapeutic research is created to conduct an <br/>
<a id="pl.15.32"></a><var>15.32</var>impact assessment of medical cannabis therapeutic research. The task force shall consist <br/>
<a id="pl.15.33"></a><var>15.33</var>of the following members:<br/>
<a id="pl.15.34"></a><var>15.34</var>    (1) two members of the house of representatives, one selected by the speaker of the <br/>
<a id="pl.15.35"></a><var>15.35</var>house, the other selected by the minority leader;<br/>
<a id="pl.16.1"></a><var>16.1</var>    (2) two members of the senate, one selected by the majority leader, the other <br/>
<a id="pl.16.2"></a><var>16.2</var>selected by the minority leader;<br/>
<a id="pl.16.3"></a><var>16.3</var>    (3) four members representing consumers or patients enrolled in the registry <br/>
<a id="pl.16.4"></a><var>16.4</var>program, including at least two parents of patients under age 18;<br/>
<a id="pl.16.5"></a><var>16.5</var>    (4) four members representing health care providers, including one licensed <br/>
<a id="pl.16.6"></a><var>16.6</var>pharmacist;<br/>
<a id="pl.16.7"></a><var>16.7</var>    (5) four members representing law enforcement, one from the Minnesota Chiefs of <br/>
<a id="pl.16.8"></a><var>16.8</var>Police Association, one from the Minnesota Sheriff's Association, one from the Minnesota <br/>
<a id="pl.16.9"></a><var>16.9</var>Police and Peace Officers Association, and one from the Minnesota County Attorneys <br/>
<a id="pl.16.10"></a><var>16.10</var>Association;<br/>
<a id="pl.16.11"></a><var>16.11</var>    (6) four members representing substance use disorder treatment providers; and<br/>
<a id="pl.16.12"></a><var>16.12</var>    (7) the commissioners of health, human services, and public safety.<br/>
<a id="pl.16.13"></a><var>16.13</var>    (b) Task force members listed under paragraph (a), clauses (3), (4), (5), and (6), shall <br/>
<a id="pl.16.14"></a><var>16.14</var>be appointed by the governor. Members shall serve on the task force at the pleasure of <br/>
<a id="pl.16.15"></a><var>16.15</var>the appointing authority.<br/>
<a id="pl.16.16"></a><var>16.16</var>    (c) There shall be two cochairs of the task force chosen from the members listed <br/>
<a id="pl.16.17"></a><var>16.17</var>under paragraph (a). One cochair shall be selected by the speaker of the house and <br/>
<a id="pl.16.18"></a><var>16.18</var>the other cochair shall be selected by the majority leader of the senate. The expense <br/>
<a id="pl.16.19"></a><var>16.19</var>reimbursement for members of the task force is governed by section 15.059.<br/>
<a id="pl.16.20"></a><var>16.20</var>    (d) Members of the task force other than those in paragraph (a), clauses (1), (2), and <br/>
<a id="pl.16.21"></a><var>16.21</var>(7), shall receive expenses as provided in section 15.059, subdivision 6.<br/>
<a id="pl.16.22"></a><var>16.22</var>    Subd. 2. <b>Impact assessment.</b> The task force shall hold hearings to conduct <br/>
<a id="pl.16.23"></a><var>16.23</var>an assessment that evaluates the impact of the use of medical cannabis and evaluate <br/>
<a id="pl.16.24"></a><var>16.24</var>Minnesota's activities and other states' activities involving medical cannabis, and offer <br/>
<a id="pl.16.25"></a><var>16.25</var>analysis of:<br/>
<a id="pl.16.26"></a><var>16.26</var>    (1) program design and implementation;<br/>
<a id="pl.16.27"></a><var>16.27</var>    (2) the impact on the health care provider community;<br/>
<a id="pl.16.28"></a><var>16.28</var>    (3) patient experiences;<br/>
<a id="pl.16.29"></a><var>16.29</var>    (4) the impact on the incidence of substance abuse;<br/>
<a id="pl.16.30"></a><var>16.30</var>    (5) access to and quality of medical products;<br/>
<a id="pl.16.31"></a><var>16.31</var>    (6) the impact on law enforcement and prosecutions;<br/>
<a id="pl.16.32"></a><var>16.32</var>    (7) public awareness and perception; and<br/>
<a id="pl.16.33"></a><var>16.33</var>    (8) any unintended consequences.<br/>
<a id="pl.16.34"></a><var>16.34</var>    Subd. 3. <b>Reports to the legislature.</b> (a) The cochairs shall submit the following <br/>
<a id="pl.16.35"></a><var>16.35</var>reports to the chairs and ranking minority members of the legislative committees and <br/>
<a id="pl.17.1"></a><var>17.1</var>divisions with jurisdiction over health and human services, public safety, judiciary, and <br/>
<a id="pl.17.2"></a><var>17.2</var>civil law:<br/>
<a id="pl.17.3"></a><var>17.3</var>    (1) by February 1, 2015, a report on the design and implementation of the registry <br/>
<a id="pl.17.4"></a><var>17.4</var>program; and<br/>
<a id="pl.17.5"></a><var>17.5</var>    (2) every two years thereafter, a complete report on the impact assessment.<br/>
<a id="pl.17.6"></a><var>17.6</var>    (b) The task force may make recommendations to the legislature on whether to add <br/>
<a id="pl.17.7"></a><var>17.7</var>or remove conditions from the list of qualifying medical conditions.<br/>
<a id="pl.17.8"></a><var>17.8</var>    Subd. 4. <b>Expiration.</b> The task force on medical cannabis therapeutic research <br/>
<a id="pl.17.9"></a><var>17.9</var>does not expire.<br/>
<br/>
<a id="bill.0.3.0"></a><a id="pl.17.10"></a><var>17.10</var>    Sec. 3. <b>[152.25] FINANCIAL EXAMINATIONS; PRICING REVIEWS.</b><br/>
<a id="pl.17.11"></a><var>17.11</var>    Subdivision 1. <b>Financial records.</b> A medical cannabis manufacturer shall maintain <br/>
<a id="pl.17.12"></a><var>17.12</var>detailed financial records in a manner and format approved by the commissioner of health, <br/>
<a id="pl.17.13"></a><var>17.13</var>and shall keep all records updated and accessible to the commissioner when requested.<br/>
<a id="pl.17.14"></a><var>17.14</var>    Subd. 2. <b>Certified annual audit.</b> A medical cannabis manufacturer shall submit <br/>
<a id="pl.17.15"></a><var>17.15</var>the results of an annual certified financial audit to the commissioner no later than <br/>
<a id="pl.17.16"></a><var>17.16</var>May 1 of each year. The annual audit shall be conducted by an independent certified <br/>
<a id="pl.17.17"></a><var>17.17</var>public accountant; the costs of such audit are the responsibility of the medical cannabis <br/>
<a id="pl.17.18"></a><var>17.18</var>manufacturer. Results of the audit shall be provided to the medical cannabis manufacturer <br/>
<a id="pl.17.19"></a><var>17.19</var>and the commissioner. The commissioner may also require another audit of the medical <br/>
<a id="pl.17.20"></a><var>17.20</var>cannabis manufacturer by a certified public accountant chosen by the commissioner with <br/>
<a id="pl.17.21"></a><var>17.21</var>the costs of the audit paid by the medical cannabis manufacturer.<br/>
<a id="pl.17.22"></a><var>17.22</var>    Subd. 3. <b>Power to examine.</b> (a) The commissioner or designee may examine the <br/>
<a id="pl.17.23"></a><var>17.23</var>business affairs and conditions of any medical cannabis manufacturer, including but not <br/>
<a id="pl.17.24"></a><var>17.24</var>limited to a review of the financing, budgets, revenues, sales, and pricing. <br/>
<a id="pl.17.25"></a><var>17.25</var>(b) An examination may cover the medical cannabis manufacturer's business affairs, <br/>
<a id="pl.17.26"></a><var>17.26</var>practices, and conditions including but not limited to a review of the financing, budgets, <br/>
<a id="pl.17.27"></a><var>17.27</var>revenues, sales, and pricing. The commissioner shall determine the nature and scope of <br/>
<a id="pl.17.28"></a><var>17.28</var>each examination and in doing so shall take into account all available relevant factors <br/>
<a id="pl.17.29"></a><var>17.29</var>concerning the financial and business affairs, practices, and conditions of the examinee. <br/>
<a id="pl.17.30"></a><var>17.30</var>The costs incurred by the department in conducting such examination shall be paid for by <br/>
<a id="pl.17.31"></a><var>17.31</var>the medical cannabis manufacturer.<br/>
<a id="pl.17.32"></a><var>17.32</var>(c) When making an examination under this section, the commissioner may retain <br/>
<a id="pl.17.33"></a><var>17.33</var>attorneys, appraisers, independent economists, independent certified public accountants, <br/>
<a id="pl.17.34"></a><var>17.34</var>or other professionals and specialists as designees. A certified public accountant retained <br/>
<a id="pl.18.1"></a><var>18.1</var>by the commissioner may not be the same certified public accountant providing the <br/>
<a id="pl.18.2"></a><var>18.2</var>certified annual audit in subdivision 2.<br/>
<a id="pl.18.3"></a><var>18.3</var>(d) The commissioner shall make a report of an examination conducted pursuant to <br/>
<a id="pl.18.4"></a><var>18.4</var>this chapter and shall provide a copy of the report to the medical cannabis manufacturer. <br/>
<a id="pl.18.5"></a><var>18.5</var>The commissioner shall then post a copy of the report on the department's Website. All <br/>
<a id="pl.18.6"></a><var>18.6</var>working papers, recorded information, documents, and copies thereof produced by, <br/>
<a id="pl.18.7"></a><var>18.7</var>obtained by, or disclosed to the commissioner or any other person in the course of an <br/>
<a id="pl.18.8"></a><var>18.8</var>examination, other than the information contained in any commissioner official report, <br/>
<a id="pl.18.9"></a><var>18.9</var>made under this subdivision is not public data.<br/>
<br/>
<a id="bill.0.4.0"></a><a id="pl.18.10"></a><var>18.10</var>    Sec. 4. Minnesota Statutes 2012, section 256B.0625, subdivision 13d, is amended to <br/>
<a id="pl.18.11"></a><var>18.11</var>read:<br/>
<a id="pl.18.12"></a><var>18.12</var>    Subd. 13d. <b>Drug formulary.</b> (a) The commissioner shall establish a drug <br/>
<a id="pl.18.13"></a><var>18.13</var>formulary. Its establishment and publication shall not be subject to the requirements of the <br/>
<a id="pl.18.14"></a><var>18.14</var>Administrative Procedure Act, but the Formulary Committee shall review and comment <br/>
<a id="pl.18.15"></a><var>18.15</var>on the formulary contents.<br/>
<a id="pl.18.16"></a><var>18.16</var>    (b) The formulary shall not include:<br/>
<a id="pl.18.17"></a><var>18.17</var>    (1) drugs, active pharmaceutical ingredients, or products for which there is no <br/>
<a id="pl.18.18"></a><var>18.18</var>federal funding;<br/>
<a id="pl.18.19"></a><var>18.19</var>    (2) over-the-counter drugs, except as provided in subdivision 13;<br/>
<a id="pl.18.20"></a><var>18.20</var>    (3) drugs or active pharmaceutical ingredients used for weight loss, except that <br/>
<a id="pl.18.21"></a><var>18.21</var>medically necessary lipase inhibitors may be covered for a recipient with type II diabetes;<br/>
<a id="pl.18.22"></a><var>18.22</var>    (4) drugs or active pharmaceutical ingredients when used for the treatment of <br/>
<a id="pl.18.23"></a><var>18.23</var>impotence or erectile dysfunction;<br/>
<a id="pl.18.24"></a><var>18.24</var>    (5) drugs or active pharmaceutical ingredients for which medical value has not <br/>
<a id="pl.18.25"></a><var>18.25</var>been established; and<br/>
<a id="pl.18.26"></a><var>18.26</var>    (6) drugs from manufacturers who have not signed a rebate agreement with the <br/>
<a id="pl.18.27"></a><var>18.27</var>Department of Health and Human Services pursuant to section 1927 of title XIX of the <br/>
<a id="pl.18.28"></a><var>18.28</var>Social Security Act.; and<br/>
<a id="pl.18.29"></a><var>18.29</var>(7) medical cannabis as defined under section 152.22.<br/>
<a id="pl.18.30"></a><var>18.30</var>    (c) If a single-source drug used by at least two percent of the fee-for-service <br/>
<a id="pl.18.31"></a><var>18.31</var>medical assistance recipients is removed from the formulary due to the failure of the <br/>
<a id="pl.18.32"></a><var>18.32</var>manufacturer to sign a rebate agreement with the Department of Health and Human <br/>
<a id="pl.18.33"></a><var>18.33</var>Services, the commissioner shall notify prescribing practitioners within 30 days of <br/>
<a id="pl.18.34"></a><var>18.34</var>receiving notification from the Centers for Medicare and Medicaid Services (CMS) that a <br/>
<a id="pl.18.35"></a><var>18.35</var>rebate agreement was not signed.<br/>
<br/>
<a id="bill.0.5.0"></a><a id="pl.19.1"></a><var>19.1</var>    Sec. 5. <b>RULES; ADVERSE INCIDENTS.</b><br/>
<a id="pl.19.2"></a><var>19.2</var>(a) The commissioner of health shall adopt rules to establish requirements for <br/>
<a id="pl.19.3"></a><var>19.3</var>reporting incidents when individuals who are not authorized to possess medical cannabis <br/>
<a id="pl.19.4"></a><var>19.4</var>under Minnesota Statutes, section 152.22, subdivision 11, are found in possession of <br/>
<a id="pl.19.5"></a><var>19.5</var>medical cannabis. The rules must identify professionals required to report, the information <br/>
<a id="pl.19.6"></a><var>19.6</var>they are required to report, and actions the reporter must take to secure the medical cannabis.<br/>
<a id="pl.19.7"></a><var>19.7</var>(b) The commissioner of health shall adopt rules to establish requirements for law <br/>
<a id="pl.19.8"></a><var>19.8</var>enforcement officials and health professionals to report incidents involving an overdose of <br/>
<a id="pl.19.9"></a><var>19.9</var>medical cannabis to the commissioner of health.<br/>
<a id="pl.19.10"></a><var>19.10</var>(c) Rules must include the method by which the commissioner will collect and <br/>
<a id="pl.19.11"></a><var>19.11</var>tabulate reports of unauthorized possession and overdose.<br/>
<br/>
<a id="bill.0.6.0"></a><a id="pl.19.12"></a><var>19.12</var>    Sec. 6. <b>INTRACTABLE PAIN.</b><br/>
<a id="pl.19.13"></a><var>19.13</var>The commissioner of health shall consider the addition of intractable pain, as defined <br/>
<a id="pl.19.14"></a><var>19.14</var>in Minnesota Statutes, section 152.125, subdivision 1, to the list of qualifying medical <br/>
<a id="pl.19.15"></a><var>19.15</var>conditions under Minnesota Statutes, section 152.22, subdivision 1, paragraph (m), prior <br/>
<a id="pl.19.16"></a><var>19.16</var>to the consideration of any other new qualifying medical conditions. The commissioner <br/>
<a id="pl.19.17"></a><var>19.17</var>shall report findings on the need for adding intractable pain to the list of qualifying <br/>
<a id="pl.19.18"></a><var>19.18</var>medical conditions to the task force established under Minnesota Statutes, section 152.24, <br/>
<a id="pl.19.19"></a><var>19.19</var>no later than July 1, 2016.<br/>
<br/>
<a id="bill.0.7.0"></a><a id="pl.19.20"></a><var>19.20</var>    Sec. 7. <b>APPROPRIATIONS, MEDICAL CANNABIS RESEARCH.</b><br/>
<a id="pl.19.21"></a><var>19.21</var>    Subdivision 1. <b>Health Department.</b> $2,795,000 is appropriated in fiscal year <br/>
<a id="pl.19.22"></a><var>19.22</var>2015 from the general fund to the commissioner of health for the costs of administering <br/>
<a id="pl.19.23"></a><var>19.23</var>Minnesota Statutes, section 152.22. The base for this appropriation is $829,000 in fiscal <br/>
<a id="pl.19.24"></a><var>19.24</var>year 2016 and $728,000 in fiscal year 2017.<br/>
<a id="pl.19.25"></a><var>19.25</var>    Subd. 2. <b>Legislative Coordinating Commission.</b> $24,000 is appropriated in <br/>
<a id="pl.19.26"></a><var>19.26</var>fiscal year 2015 from the general fund to the Legislative Coordinating Commission to <br/>
<a id="pl.19.27"></a><var>19.27</var>administer the task force on medical cannabis therapeutic research and for the task force to <br/>
<a id="pl.19.28"></a><var>19.28</var>conduct the impact assessment on the use of cannabis for medicinal purposes.<br/>
<a id="pl.19.29"></a><var>19.29</var>    Subd. 3. <b>Health Department.</b> $24,000 in fiscal year 2015 is appropriated from the <br/>
<a id="pl.19.30"></a><var>19.30</var>state government special revenue fund to the commissioner of health for the costs of <br/>
<a id="pl.19.31"></a><var>19.31</var>implementing Minnesota Statutes, section 152.22. The base for this appropriation is <br/>
<a id="pl.19.32"></a><var>19.32</var>$734,000 in fiscal year 2016 and $722,000 in fiscal year 2017.<br/>
<br/>
<a id="bill.0.8.0"></a><a id="pl.20.1"></a><var>20.1</var>    Sec. 8. <b>EFFECTIVE DATE.</b><br/>
<a id="pl.20.2"></a><var>20.2</var>Sections 1 to 7 are effective the day following final enactment.<br/>